Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer
Journal
Beilstein journal of nanotechnology
Date Issued
2023-02-22
Author(s)
Gorachinov, Filip
Mraiche, Fatima
Moustafa, Diala Alhaj
Hishari, Ola
Ismail, Yomna
Joseph, Jensa
DOI
10.3762/bjnano.14.23
Abstract
Genomic and proteomic mutation analysis is the standard of care for selecting candidates for therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor (EGFR TKI therapies) and further monitoring cancer treatment efficacy and cancer development. Acquired resistance due to various genetic aberrations is an unavoidable problem during EGFR TKI therapy, leading to the rapid exhaustion of standard molecularly targeted therapeutic options against mutant variants. Attacking multiple molecular targets within one or several signaling pathways by co-delivery of multiple agents is a viable strategy for overcoming and preventing resistance to EGFR TKIs. However, because of the difference in pharmacokinetics among agents, combined therapies may not effectively reach their targets. The obstacles regarding the simultaneous co-delivery of therapeutic agents at the site of action can be overcome using nanomedicine as a platform and nanotools as delivery agents. Precision oncology research to identify targetable biomarkers and optimize tumor homing agents, hand in hand with designing multifunctional and multistage nanocarriers that respond to the inherent heterogeneity of the tumors, may resolve the challenges of inadequate tumor localization, improve intracellular internalization, and bring advantages over conventional nanocarriers.
Subjects
File(s)![Thumbnail Image]()
Loading...
Name
Beilstein_J_Nanotechnol-14-240.pdf
Size
15.65 MB
Format
Adobe PDF
Checksum
(MD5):b04728bd3528f7e894bbf93074c5519b